膦甲酸钠氯化钠联合常规治疗对人乳头瘤病毒宫颈感染的干预效果
|
摘要
目的:观察膦甲酸钠氯化钠联合常规治疗对人乳头瘤病毒宫颈感染的临床效果。方法:选取笔者所在医院92例HPV宫颈感染患者,按随机数表法分为观察组与对照组,各46例。对照组采取重组人干扰素α2b栓进行治疗,时间3个月;观察组在此基础上联合膦甲酸钠氯化钠注射液,连续静脉滴注2周。比较两组治疗总有效率、治疗前后宫颈炎评分、衣原体(CT)阳性、支原体(Uu)阳性、CT与Uu混合阳性患者的HPV转阴率及总转阴率。结果:两组治疗总有效率91.30%,高于对照组的76.09%,差异有统计学意义(X~2=3.903,P=0.048)。治疗后观察组和对照组的糜烂面大小、炎症程度、阴道清洁度及宫颈炎总评分均较治疗前降低,差异均有统计学意义(P<0.001)。观察组治疗后的糜烂面大小、炎症程度、阴道清洁度及宫颈炎总评分均低于对照组,差异均有统计学意义(t=6.917、8.544、9.605、8.119,P<0.001)。两组CT阳性、Uu阳性、CT与Uu混合阳性患者的HPV转阴率比较,差异无统计学意义(X~2=0.140、0.132、1.239,P=0.709,0.716、0.266)。观察组总转阴率达84.78%,高于对照组的65.22%,差异有统计学意义(X~2=4.696,P=0.030)。结论:膦甲酸钠联合重组人干扰素α2b栓治疗HPV宫颈感染患者可有效降低HPV病毒载量,减轻宫颈炎症并提高HPV转阴率,疗效显著,优于重组人干扰素α2b栓单一治疗。
Objective:To observe the efficacy of Sodium Foscarnet Sodium Chloride combined with conventional therapy in the treatment of human papillomavirus cervical infection.Method:A total of 92 HPV cervical infection patients in our hospital were divided into observation group and control group according to the random number table method,46 cases each group.The control group was treated with Recombinant Human Interferon α2b Suppository for 3 months;the observation group was combined with Sodium Foscarnet Sodium Chloride Injection continuously for 2 weeks.The indexes were compared between the two groups in total effective rate,cervicitis score before and after treatment,the HPV negative rate and total negative rate of CT positive,Uu positive,and CT and Uu mixed positive patients.Result:The total effective rate of the two groups was 91.30%,which was higher than 76.09% of the control group( 字2=3.903,P=0.048).After treatment,the erosion size,inflammation,vaginal cleanliness,and total cervicitis scores in the observation group and the control group were both decreased compared with before treatment(P<0.001).After treatment,the size of erosion surface,inflammation,vaginal cleanliness,and total cervicitis scores were lower in the observation group than in the control group(t=6.917,8.544,9.605,8.119,P<0.001).There were no significant differences in HPV negative rate between the two groups with CT positive,Uu positive,CT and Uu mixed positive patients( 字2=0.140,0.132,1.239,P=0.709,0.716,0.266).The total negative rate in the observation group was 84.78%,which was higher than 65.22% in the control group,the difference was statistically significant( 字2=4.696,P=0.030).Conclusion:Sodium Foscarnet Sodium Chloride combined with Recombinant Human Interferon α2b Suppository can effectively reduce the viral load of HPV,reduce cervical inflammation and increase the negative rate of HPV in patients with cervical infection of HPV.The curative effect is significant and superior to that of Recombinant Human Interferon α2b Suppository.
Objective:To observe the efficacy of Sodium Foscarnet Sodium Chloride combined with conventional therapy in the treatment of human papillomavirus cervical infection.Method:A total of 92 HPV cervical infection patients in our hospital were divided into observation group and control group according to the random number table method,46 cases each group.The control group was treated with Recombinant Human Interferon α2b Suppository for 3 months;the observation group was combined with Sodium Foscarnet Sodium Chloride Injection continuously for 2 weeks.The indexes were compared between the two groups in total effective rate,cervicitis score before and after treatment,the HPV negative rate and total negative rate of CT positive,Uu positive,and CT and Uu mixed positive patients.Result:The total effective rate of the two groups was 91.30%,which was higher than 76.09% of the control group( 字2=3.903,P=0.048).After treatment,the erosion size,inflammation,vaginal cleanliness,and total cervicitis scores in the observation group and the control group were both decreased compared with before treatment(P<0.001).After treatment,the size of erosion surface,inflammation,vaginal cleanliness,and total cervicitis scores were lower in the observation group than in the control group(t=6.917,8.544,9.605,8.119,P<0.001).There were no significant differences in HPV negative rate between the two groups with CT positive,Uu positive,CT and Uu mixed positive patients( 字2=0.140,0.132,1.239,P=0.709,0.716,0.266).The total negative rate in the observation group was 84.78%,which was higher than 65.22% in the control group,the difference was statistically significant( 字2=4.696,P=0.030).Conclusion:Sodium Foscarnet Sodium Chloride combined with Recombinant Human Interferon α2b Suppository can effectively reduce the viral load of HPV,reduce cervical inflammation and increase the negative rate of HPV in patients with cervical infection of HPV.The curative effect is significant and superior to that of Recombinant Human Interferon α2b Suppository.
引文
[1]李智敏,曾俐琴,彭秀红,等.高危型HPV阴性子宫颈癌患者的临床病理特点[J].中华妇产科杂志,2016,51(9):683-687.
[2]福建省海峡两岸精准医学协会HPV感染疾病专业委员会.HPV感染疾病相关问题专家共识(2017)[J].医学研究生学报,2017,30(12):1238-1241.
[3]杨明珠,李亚军,王文素,等.女性HPV亚型的感染情况及与宫颈癌的相关性[J].中国实验诊断学,2016,20(8):1331-1333.
[4]杜亚丽,吕蓓,朱雷芳,等.重组人干扰素α-2b联合膦甲酸钠治疗宫颈HPV感染的临床疗效观察[J].现代生物医学进展,2016,16(34):6673-6675.
[5]王丽军.重组人干扰素α-2b凝胶联合膦甲酸钠氯化钠治疗宫颈HPV高危型感染的临床观察[J].齐齐哈尔医学院学报,2016,37(25):3173-3174.
[6]李秀霞.影响HPV感染的相关因素及膦甲酸钠氯化钠的治疗效果[J].中国妇幼保健,2016,31(2):438-439.
[7]杨彩虹,孟焕然,万颖,等.膦甲酸钠氯化钠联合重组人干扰素α-2b栓治疗宫颈癌前病变合并HPV高危型感染的临床疗效[J].癌症进展,2016,14(12):1249-1251,1274.
[8]徐美玉.膦甲酸钠氯化钠联合保妇康栓治疗高危型HPV感染宫颈炎的临床研究[J].实用临床医药杂志,2015,19(21):174-175.
[9]罗敏.重组人干扰素α-2b栓联合膦甲酸钠氯化钠治疗人乳头状瘤病毒感染宫颈炎的效果研究[J].北方药学,2015,12(9):98-99.
[10]陈丽娟,强萍,陈萍,等.宫颈癌前病变伴HPV高危型感染患者膦甲酸钠氯化钠注射液治疗的效果研究[J].中华医院感染学杂志,2015,25(20):4764-4766.
[11]朱铮,毛利云.尤靖安.膦甲酸钠及其联合治疗HPV感染的临床研究[J].湖南师范大学学报:医学版,2017,14(6):142-144.
[12]张珊,洪颖,马莉,等.宫颈细胞学阴性HPV阳性妇女的HPV分型检测[J].山东医药,2015,55(43):5-7.
[13]苗钢,赵晶辉,陈岩,等.卡介菌多糖核酸联合膦甲酸钠治疗带状疱疹的临床疗效观察[J].国际病毒学杂志,2015,22(4):236-239.
[2]福建省海峡两岸精准医学协会HPV感染疾病专业委员会.HPV感染疾病相关问题专家共识(2017)[J].医学研究生学报,2017,30(12):1238-1241.
[3]杨明珠,李亚军,王文素,等.女性HPV亚型的感染情况及与宫颈癌的相关性[J].中国实验诊断学,2016,20(8):1331-1333.
[4]杜亚丽,吕蓓,朱雷芳,等.重组人干扰素α-2b联合膦甲酸钠治疗宫颈HPV感染的临床疗效观察[J].现代生物医学进展,2016,16(34):6673-6675.
[5]王丽军.重组人干扰素α-2b凝胶联合膦甲酸钠氯化钠治疗宫颈HPV高危型感染的临床观察[J].齐齐哈尔医学院学报,2016,37(25):3173-3174.
[6]李秀霞.影响HPV感染的相关因素及膦甲酸钠氯化钠的治疗效果[J].中国妇幼保健,2016,31(2):438-439.
[7]杨彩虹,孟焕然,万颖,等.膦甲酸钠氯化钠联合重组人干扰素α-2b栓治疗宫颈癌前病变合并HPV高危型感染的临床疗效[J].癌症进展,2016,14(12):1249-1251,1274.
[8]徐美玉.膦甲酸钠氯化钠联合保妇康栓治疗高危型HPV感染宫颈炎的临床研究[J].实用临床医药杂志,2015,19(21):174-175.
[9]罗敏.重组人干扰素α-2b栓联合膦甲酸钠氯化钠治疗人乳头状瘤病毒感染宫颈炎的效果研究[J].北方药学,2015,12(9):98-99.
[10]陈丽娟,强萍,陈萍,等.宫颈癌前病变伴HPV高危型感染患者膦甲酸钠氯化钠注射液治疗的效果研究[J].中华医院感染学杂志,2015,25(20):4764-4766.
[11]朱铮,毛利云.尤靖安.膦甲酸钠及其联合治疗HPV感染的临床研究[J].湖南师范大学学报:医学版,2017,14(6):142-144.
[12]张珊,洪颖,马莉,等.宫颈细胞学阴性HPV阳性妇女的HPV分型检测[J].山东医药,2015,55(43):5-7.
[13]苗钢,赵晶辉,陈岩,等.卡介菌多糖核酸联合膦甲酸钠治疗带状疱疹的临床疗效观察[J].国际病毒学杂志,2015,22(4):236-239.